6620.TWO · HANDA PHARMA
Taiwan · RS rating 92 · As of 2026-10-08
| Price | 127.50 TWD |
|---|---|
| 1-day change | +2.0% |
| RS rating (overall / 1M / 3M / 12M) | 92 / 85 / 93 / 61 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 48 / 56 / 28 |
| Industry group (rank) | Medical-Biomed/Biotech (53) |
| EPS growth Q/Q | -57.8% |
| Sales growth Q/Q | +1.1% |
| Distance from 52-week high | +14.4% |
| Market cap (USD) | $730.4M |